Ambrx?, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques designed to create a mixture of suboptimal molecules, Ambrx’s technology combines site specific conjugation with proprietary linkers, payloads and PK extenders optimized for safety, efficacy and biophysical properties.
By using conjugation chemistries that are orthogonal to the native twenty amino acids, the company creates antibody conjugates with unprecedented homogeneity with respect to the site of drug attachment. Furthermore, quantitative experimentation with homogenous antibody conjugates enables an efficient, robust and science driven path for optimizing efficacy, safety and biophysical properties to meet target product profiles.
Ambrx is developing antibody drug conjugates (ADCs) for oncology as well as non-oncology indications. The company’s?ADCs have demonstrated high potency and a significantly wider therapeutic index than ADCs created using conventional non-specific conjugation.
10975 North Torrey Pines Road
La Jolla, CA 92037
U.S.A.
Web:?Ambrx Inc.
